Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content
- PMID: 9848500
- DOI: 10.1093/ajcn/68.6.1364S
Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content
Abstract
Our previous studies showed that a soy-protein diet prevents ovariectomy-induced bone loss. The purpose of this study was to determine whether isoflavones in soy protein are responsible for this bone-protective effect. Forty-eight 95-d-old Sprague-Dawley rats were divided into 4 groups: sham-operated fed a casein-based diet (SHAM), ovariectomized fed a casein-based diet (OVX+CASEIN), ovariectomized fed soy protein with normal isoflavone content (OVX+SOY), and ovariectomized fed soy protein with reduced isoflavone content (OVX+SOY-). The OVX+SOY group had significantly greater femoral bone density (in g/cm3 bone vol) than the OVX+CASEIN group, whereas OVX+SOY- was similar to OVX+CASEIN (mean +/- SD; SHAM, 1.522 +/- 0.041; OVX+CASEIN, 1.449 +/- 0.044; OVX+SOY, 1.497 +/- 0.030; OVX+SOY-, 1.452 +/- 0.030). Ovariectomy resulted in greater bone turnover as indicated by higher serum alkaline phosphatase activity, serum insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations, and urinary hydroxyproline. These increases were not affected by soy with either normal or reduced isoflavone content. Similarly, histomorphometry revealed a greater bone formation rate with ovariectomy, and this was not altered by the soy diets. The findings of this study suggest that isoflavones in soy protein are responsible for its bone-sparing effects. Further studies to evaluate the mechanism of action of isoflavones on bone are warranted.
Similar articles
-
Role of soy protein with normal or reduced isoflavone content in reversing bone loss induced by ovarian hormone deficiency in rats.Am J Clin Nutr. 1998 Dec;68(6 Suppl):1358S-1363S. doi: 10.1093/ajcn/68.6.1358S. Am J Clin Nutr. 1998. PMID: 9848499
-
Soy moderately improves microstructural properties without affecting bone mass in an ovariectomized rat model of osteoporosis.Bone. 2006 May;38(5):686-93. doi: 10.1016/j.bone.2005.10.024. Epub 2006 Jan 10. Bone. 2006. PMID: 16406762
-
Soy protein with or without isoflavones failed to preserve bone density in gonadal hormone-deficient male rat model of osteoporosis.Nutr Res. 2012 Sep;32(9):694-700. doi: 10.1016/j.nutres.2012.08.001. Epub 2012 Sep 23. Nutr Res. 2012. PMID: 23084642
-
Can soy prevent male osteoporosis? A review of the current evidence.Curr Drug Targets. 2013 Dec;14(14):1632-41. doi: 10.2174/1389450114666131216222612. Curr Drug Targets. 2013. PMID: 24354587 Review.
-
Mechanism of Soy Isoflavone Daidzein-Induced Female-Specific Anorectic Effect.Metabolites. 2022 Mar 16;12(3):252. doi: 10.3390/metabo12030252. Metabolites. 2022. PMID: 35323695 Free PMC article. Review.
Cited by
-
Modulation of soy isoflavones bioavailability and subsequent effects on bone health in ovariectomized rats: the case for equol.Osteoporos Int. 2007 May;18(5):671-9. doi: 10.1007/s00198-007-0351-y. Epub 2007 Feb 28. Osteoporos Int. 2007. PMID: 17333448
-
Soy protein consumption and bone mass in early postmenopausal Chinese women.Osteoporos Int. 2003 Oct;14(10):835-42. doi: 10.1007/s00198-003-1453-9. Epub 2003 Aug 14. Osteoporos Int. 2003. PMID: 12920508 Review.
-
Understanding the Composition, Biosynthesis, Accumulation and Transport of Flavonoids in Crops for the Promotion of Crops as Healthy Sources of Flavonoids for Human Consumption.Nutrients. 2020 Jun 8;12(6):1717. doi: 10.3390/nu12061717. Nutrients. 2020. PMID: 32521660 Free PMC article. Review.
-
Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis.Drug Saf. 2001;24(9):665-82. doi: 10.2165/00002018-200124090-00003. Drug Saf. 2001. PMID: 11522120 Review.
-
Effect of whole soy and isoflavones daidzein on bone turnover and inflammatory markers: a 6-month double-blind, randomized controlled trial in Chinese postmenopausal women who are equol producers.Ther Adv Endocrinol Metab. 2020 Jun 18;11:2042018820920555. doi: 10.1177/2042018820920555. eCollection 2020. Ther Adv Endocrinol Metab. 2020. PMID: 32595918 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical